Teleflex

TFX · NYSE

$131.15+$1.47 (+1.13%)TodayMarket closed · Oct 20, 7:00 PM ET

Prev close $129.68

TFX analyst rating

BuyConsensus of 12 analysts over the last 12 months. 58% rate it a buy.

Strong buy0
Buy7
Hold5
Underperform0
Sell0

12-month price target · 14 analysts

Average $156.97 (+19.7% upside)

Low: $139.38
Now: $131.15
High: $178.50

Upgrades and downgrades

The latest rating actions, newest first

TFX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Oct 14, 2026	Maintains	Hold	$150.00 → $142.00	50%
B of A Securities	Sep 28, 2026	Upgrade	Neutral → Buy	$145.00 → $158.00	66%
Needham	Aug 25, 2026	Maintains	Buy	$159.00 → $170.00	45%
UBS	Aug 11, 2026	Maintains	Neutral	$145.00 → $158.00	43%
Truist Securities	Aug 10, 2026	Maintains	Hold	$143.00 → $150.00	33%
Piper Sandler	Aug 7, 2026	Maintains	Overweight	$160.00 → $169.00	43%
Needham	Jul 31, 2026	Maintains	Buy	$147.00 → $159.00	45%
UBS	Jul 28, 2026	Initiates	Neutral	$145.00	43%
Mizuho	Jul 15, 2026	Maintains	Neutral	$140.00 → $145.00	56%
BMO Capital	Jul 9, 2026	Initiates	Outperform	$159.00	45%

The case for and against

Updated Oct 18, 2026

Bull case

Teleflex is supported by a credible growth engine in Freesolve, a sirolimus-eluting resorbable magnesium scaffold that may avoid the limitations of permanent metal stents and has already shown low target lesion failure, vessel recovery benefits, and a strong safety profile. With BIOMAG-II fully enrolled in 1,861 patients across 100 sites in 21 countries and results due in late 2027, success could expand international adoption, drive guideline support, and add 1-2% to annual revenue growth in 2028+ while commanding a premium over DES pricing. The company also delivered 2Q revenue of $570.3M, adjusted gross margin of 61.7%, and adjusted operating margin of 19.6%, while management’s cost actions, debt paydown, and buybacks support higher EPS and margin normalization.

Bear case

Teleflex is facing a cautious setup because slower-than-expected growth in key drivers, weaker margin improvement, and potentially dilutive acquisitions could pressure earnings power. Management’s portfolio actions, including the Biotronik vascular acquisition and plans to spin off or sell Urology, Acute care, and OEM, may create value only if executed cleanly, yet integration is already taking longer than expected due to ordering-process changes, distributor transitions, and sales-force disruptions. Despite compressed valuation and some downside support, the company’s heavy exposure to Americas revenue and the uncertainty around a complex break-up leave limited confidence in near-term fundamental improvement.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.